Intravitreal Anti-Vascular Endothelial Growth Factor Medications During Pregnancy: Current Perspective Publisher Pubmed



Naderan M¹ ; Sabzevary M² ; Rezaii K¹ ; Banafshehafshan A¹ ; Hantoushzadeh S³ Show Affiliations
Source: International Ophthalmology Published:2021

Abstract

Purpose: Anti-vascular endothelial growth factor (VEGF) medications are widely used for treatment of a number of vitreoretinal disorders. However, the evidence for their effect on fetal and maternal health during pregnancy is very limited. The goal of this article is to accumulate evidence for the indications of anti-VEGF medications during pregnancy and their effects on maternal and fetal health. Methods: Review of literature regarding anti-VEGF administration during pregnancy and using PubMed database without language or date limit. Results: The main indications for treatment with intravitreal anti-VEGF medications include choroidal neovascularization (CNV) followed by retinal vascular occlusion (RVO) and complications of diabetes such as neovascular glaucoma, diabetic retinopathy (DR) and diabetic macular edema (DME). Among anti-VEGF medications, only ranibizumab and bevacizumab have been used during pregnancy with latter by far more than the former. Conclusion: Women of childbearing age should be consulted regarding the potential adverse effects of anti-VEGF medications on fetal health and the risk of early pregnancy loss. They should be strongly encouraged to use appropriate contraceptive methods during treatment. A timely obstetrics consultation may help in this situation. Attempt for pregnancy should be withheld for at least 3 months following last injection of ranibizumab and aflibercept, and for at least 6 months following last injection of bevacizumab. © 2020, Springer Nature B.V.